Author/Authors :
Kensuke Matsumoto، نويسنده , , Koji Murao، نويسنده , , Hitomi Imachi، نويسنده , , Takamasa Nishiuchi، نويسنده , , Wenming Cao، نويسنده , , Xiao Yu، نويسنده , , Junhua Li، نويسنده , , Rania A.M. Ahmed، نويسنده , , Hisakazu Iwama، نويسنده , , Ryoji Kobayashi، نويسنده , , Hiroshi Tokumitsu، نويسنده , , Toshihiko Ishida، نويسنده ,
Abstract :
Objective
Adult T-cell leukemia (ATL) is a mature CD4+ T-cell malignancy caused by infection with human T-lymphotrophic virus type-1 and is associated with a marked hypercalcemia in many patients. Recently, it has been proposed that macrophage inflammatory protein-1α (MIP-1α) is the clinical hallmark of hypercalcemia in ATL. In this study, we investigated the effect of extracellular calcium on MIP-1α secretion in ATL cells and the role of Ca2+/calmodulin (CaM)-dependent protein kinase (CaM-K) cascade in transcriptional activation of MIP-1α.
Materials and Methods
MIP-1α protein levels in the culture supernatant collected from ATL cells were measured by enzyme-linked immunosorbent assay. Reporter plasmid containing the MIP-1α promoter was transfected to ATL cells, and the promoter activity was measured by luciferase assay.
Results
The addition of calcium to the culture medium enhanced the secretion of MIP-1α from ATL cells, which was inhibited by the CaM-KK inhibitor. The transfection of CaM-KIV stimulated MIP-1α promoter activity, and the upstream kinase CaM-KK enhanced the stimulatory effect of CaM-KIV on the promoter activity. Mutation in the cyclic adenosine 5′ monophosphate response element (CRE) within the MIP-1α promoter significantly reduced the effect of CaM-KIV, and CRE mutant promoter activity was not significantly enhanced by the addition of calcium to the culture medium as compared to wild-type promoter activity.
Conclusion
Hypercalcemia enhances MIP-1α secretion in ATL cells, and this mechanism requires the involvement of CaM-KK/CaM-KIV cascade through the CRE. These findings raise a possibility that the inhibitory effect of CaM-KK/CaM-KIV cascade may be a potential therapeutic target for ATL.